Member Info for K3VMC

There is often more than one reason for taking a course of action. The good reason and the real reason. Yes, this is nominally a safety and tolerability extension test (good reason), but what you conveniently forgot to mention is the secondary target (and in my view real reason). Secondary Outcome Measures : the effect in the Clinical SLEDAI-2K total score by at final visit compared to initial visit [ Time Frame: at week 28 ] The SLEDAI 2K is a validated objective measure that assesses disease activity within the last 28 days before completion of the index. It is a global index and includes 24 weighted clinical and laboratory variables. The SLEDAI-2K clinical score is the calculated score without inclusion of the points that may be contributed by having a psoitive titer fr anti-dsdna Ab or decreased serum complement level. The SLEDAI-2K clinical score (sum of 22 scores) ranges from 0 to 101. Remission of the disease (i.e reduction of clinical SLEDAI-2K score to 0) [ Time Frame: at week 28 ] Inclusion of that target makes a whole lot of difference to the slant you put on it.

Nolupus you state that the extension trial is only about safety. That is a blatant untruth, as demonstrated by the RNS Separately, as previously announced, following requests from both Investigators and patients involved in the Phase III study, ImmuPharma has initiated an additional study permitting all patients who participated in the Phase III study, to receive Lupuzor� (plus "Standard of Care") for six months in an open-label scheme. The results will be gathered as an "extension" open label study, independent of the pivotal Phase III trial. The Company looks forward to providing further updates regarding this study in due course. Why would any patient want to remain on a treatment for six months, just to prove it is safe? That makes no sense. This is patently a means of providing further and better particulars, which will be added to the detailed analysis of the p3 data and presenting that to the FDA and/or the double digit number of pharma that IMM told us about. You are entitled to your own opinion, whether that is honest or not, but you are NOT entitled to your own facts.

Teabiscuit, my take is that IMM will have enough data from p3 and the extended trial to get this past the FDA. Massive unmet medical need. No deaths. Chance of complete remission. Asymmetric risk/reward ratio.

Dagnabit, RR is back!! My order this morning was not filled as WRES is currently very well bid.I was tempted to pay a premium (yet again) to fill it, but was too tight to pay the extra. Had I known that RR is posting again, i would have upped my price.

Lupuzor works. No other treatment provided complete remission at ANY level, so7.6% is a great start. Unlike Benlysta, there are no serious side effects. NOT a hint of , well, DEATH. Only 13,000 out of 5,000,000 sufferers worldwide being treated, at huge expense. There is a great unmed medical requirement to treat Lupus On-going open trial. IMM in talks with big pharma.

Courtier, i was miffed that Mr Menzies left before we had a chance to speak to him. I was informed that he had to travel somewhere. Hopefully, Indonesia.

Definitely not. Better off with WLFE.

grippa, they raised �14m in January, so maybe �13m? It may well have been me grilling the CFO, if you mean the presentation at the Ritz. I was arguing for warrants to be attached to shares in the proposed open offer. Warrant to be exercised are per the recent rns.

Falanx, as i see it, is providing a library of objects that their customer devops team can reuse in their own software. No large client wants to depend on a third party to run their security, but they want trusted, effective and reliable code, plus access to information on every evolving threats, in real time. With Security as a Service, customers have up to the minute information, without regularly upgrading their software. Very clever indeed.

Good morning all! Yes Bob. Mr Masterman showed a photo of the enlarged team. Looked like 11 or 13 bods sitting at a long table. He said some of the Fortescue Folks were experienced specialists in plant construction.

Not imported. Just recycled. Sadly.

Thanks SafetyMan.

Jaf, yes the loan is more expensive than in the August 2017 presentation. I reckon WRES will repay sometime in year 3, so including penalties, under $15m in interest. I can live with that.

*banging

Jaf, you made a claim. I asked you to back up the claim. You declined. Fair enough, but why bother banking the gong, if you have nothing to serve up? Only asking.

Jaf1948, with respect, you are the one who came on here as the know-it-all, not me. I know my figures, thank you. I advised you to buy at 0.26p, but you chose to sell at 0.28p. That was your real mistake. Getting a few figures wrong here or there is piffling compared to that.

IPP-204106, an anti-cancer nucleolin antagonis peptide program that has completed Phase I/IIa clinical trials to treat cancer IPP-102199, which is in pre-clinical development stage to treat severe pain IPP-201007 that is in early development stage for the treatment of inflammatory and allergic conditions, such as asthma and other respiratory disorders, rheumatoid arthritis, septic shock, and acute pancreatitis IPP-203101, a peptide antibiotic, which is in pre-clinical development stage for the treatment of lethal infections, including methicillin-resistant staphylococcus aureus and other hospital acquired infections. ALL on top of Lupuzor. Shorts will close at some point. Boing!!

jaf1948, you have corrected nothing, with all due respect. 1. What was the old cost of servicing the loan? 2. What is the new cost of servicing the loan? 3. What is the difference. Since you claim the cost has increased, I assume that you can answer these three simple questions. :-)

It is still too early to understand why this is the case and there are a number of possible causes that the Company are investigating including, inter alia, formulation, administration and deactivation. Further detailed analysis of the data and testing of product batches still needs to be conducted, and therefore there is no guarantee that this will ultimately prove to be conclusive or, of the resultant implications of that analysis. Any director can buy, as long as they have no more information than the market at large. A director purchase does NOT rule out a material RNS. Indeed, the Japan results can be completely different, resulting in a positive RNS. Clear, bright blue sky RNS, is what this calls for. :-)

Same numbers.